AZD5492

Phase 1Small molecule

AstraZeneca

AZD5492 is one of 70 small molecule programs targeting B-cell Malignancies. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

B-Cell MalignanciesRecruiting

Systemic Lupus ErythematosusRecruiting

B-Cell MalignanciesPreclinical

Recruiting

Systemic Lupus ErythematosusPhase 1

Recruiting

Competition

Competitive Landscape

134 competitors in Systemic Lupus Erythematosus

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

9 2

Medrol

Pfizer

Phase 3

5 3

Rinvoq

AbbVie

Phase 3

3 4

Cytoxan

BBaxter Healthcare Corporation

Phase 3

12 5

Gazyva

Roche

Phase 3

2 6

Sotyktu

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

3 7

Rapamune

PPrism Pharmaceuticals

Phase 3

1 8

Ianalumab

Novartis

Phase 3

3 9

Fludara

Sanofi

Phase 2

6 10

Glucocorticoid

AbbVie

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Systemic Lupus Erythematosus

NCT06916806

Q4 2029

PreclinicalRecruiting

B-Cell Malignancies

NCT06542250

Clinical

Trials by Indication[1]

Systemic Lupus Erythematosus1 trial

An Open-label, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 Following Single-ascending Dose and Step-up Dose Administration to Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis

Recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT06916806·72 enrolled

B-cell Malignancies1 trial

A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With Relapsed or Refractory B-Cell Malignancies (TITANium)

Recruiting· AstraZeneca logo

AstraZeneca·Preclinical·NCT06542250·174 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for AZD5492. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AZD5492 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AZD5492. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AstraZeneca

AZD5492

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2029

Trials by Indication[1]

Systemic Lupus Erythematosus1 trial

B-cell Malignancies1 trial

References

Drug Info

Quick Facts

Related News